UBS AG Reaffirms Buy Rating on Cardinal Health (CAH)

By admin | 4 years ago

Cardinal Health (NYSE: CAH)‘s stock had its “buy” rating restated by equities researchers at UBS AG (NYSE: UBS) in a report issued on Friday.

Shares of Cardinal Health traded up 0.37% during mid-day trading on Friday, hitting $42.86. Cardinal Health has a 52 week low of $37.53 and a 52 week high of $47.06. The company has a market cap of $14.800 billion and a P/E ratio of 14.47.


Cardinal Health last announced its earnings results on Thursday, May 3rd. The company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.06. The company’s revenue for the quarter was up 3.2% on a year-over-year basis. On average, analysts predict that Cardinal Health will post $0.85 earnings per share next quarter.

Separately, analysts at Zacks downgraded shares of Cardinal Health from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, February 23rd. They now have a $43.00 price target on the stock.

Cardinal Health, Inc. (Cardinal Health) is a global healthcare solutions company providing products and services to hospitals, physician offices and pharmacies.

Related Post